[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100505400":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":37,"responsibleParty":53,"collaborators":26,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":26,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":26,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":26,"overallStatus":39,"whyStopped":26,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"First Affiliated Hospital, Sun Yat-Sen University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"2 cycles","EXPERIMENTAL","2 cycles induction + concurrent chemoradiotherapy",[13],"Drug: 2 cycles induction chemotherapy",{"label":15,"type":16,"description":17,"interventionNames":18},"3 cycles","ACTIVE_COMPARATOR","3 cycles induction + concurrent chemoradiotherapy",[19],"Drug: 3 cycles induction chemotherapy",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","2 cycles induction chemotherapy","Drug: 2 cycles Induction Chemotherapy Induction regimens: TP (docetaxel 75 mg\u002Fm²; cisplatin 75 mg\u002Fm²) Q3w, TPF (docetaxel 60 mg\u002Fm²; cisplatin 60 mg\u002Fm²; 5-fluorouracil 600-750 mg\u002Fm² per day, continuous intravenous infusion d1-5) Q3w, or GP (gemcitabine: 1000 mg\u002Fm2 d1, d8; cisplatin 80 mg\u002Fm2) Q3w.\n\nDrug: Concurrent Chemotherapy Cisplatin 100 mg\u002Fm², Q3w.\n\nRadiation: Definitive Radiotherapy For all patients, the prescribed dose is 66-70 Gy (once a day, 5 times a week).",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"3 cycles induction chemotherapy","Drug: 3 cycles Induction Chemotherapy Induction regimens: TP (docetaxel 75 mg\u002Fm²; cisplatin 75 mg\u002Fm²) Q3w, TPF (docetaxel 60 mg\u002Fm²; cisplatin 60 mg\u002Fm²; 5-fluorouracil 600-750 mg\u002Fm² per day, continuous intravenous infusion d1-5) Q3w, or GP (gemcitabine: 1000 mg\u002Fm2 d1, d8; cisplatin 80 mg\u002Fm2) Q3w.\n\nDrug: Concurrent Chemotherapy Cisplatin 100 mg\u002Fm², Q3w.\n\nRadiation: Definitive Radiotherapy For all patients, the prescribed dose is 66-70 Gy (once a day, 5 times a week).",[15],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Cheng-Tao Wang","CONTACT","+862087755766","wangcht5@mail.sysu.edu.cn",[38],{"facility":5,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"RECRUITING","Guangzhou","Other (Non U.s.)","510080","China","CN",{"type":46,"coordinates":47},"Point",[48,49],113.25,23.11667,{"lat":49,"lon":48},[52],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},{"type":54,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Chen Yong","Prof.","100505400","phase-3-two-cycles-vs-three-cycles-induction-chemotherapy-in-t1-4n2-3-locally-advanced-nasopharyngeal-carcinoma-100505400",false,"NCT05860868","Two Cycles VS Three Cycles Induction Chemotherapy in T1-4N2-3 Locally Advanced Nasopharyngeal Carcinoma","Two Cycles VS Three Cycles Induction Chemotherapy Plus Concurrent Chemoradiotherapy in T1-4N2-3 Locally Advanced Nasopharyngeal Carcinoma","Inclusion Criteria:\n\n1. Age 18-65 years old;\n2. Pathologically confirmed non-keratinizing nasopharyngeal carcinoma;\n3. Stage T3-4N0-1 (according to the UICC\u002FAJCC 8th);\n4. No distant metastasis;\n5. Have not received anti-cancer treatment in the past;\n6. ECOG (Eastern Cooperative Oncology Group of the United States): 0-1;\n7. Adequate hematologic, hepatic and renal function.\n\nExclusion Criteria:\n\n1. The purpose of treatment is palliative;\n2. Diagnosed with other malignant tumors at the same time;\n3. Malignant tumor history;\n4. Pregnancy or breastfeeding, or expect to become pregnant during the clinical trial period;\n5. Combined serious illness.","ALL","18 Years","65 Years",{"count":68,"type":69},474,"ESTIMATED","INTERVENTIONAL",[72],"PHASE3","This trial is a multi-center phase III clinical trial. The purpose of this trial is to explore whether 2 cycles induction chemotherapy combined with concurrent chemoradiotherapy is not inferior to 3 cycles induction chemotherapy combined with concurrent chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma.",[75],"Locally Advanced Nasopharyngeal Carcinoma","2023-05-06",{"date":78,"type":79},"2023-05-16","ACTUAL",{"date":81,"type":69},"2023-05",{"date":83,"type":69},"2030-05",{"name":5,"class":6},1]